Related Experiment Video
Updated: May 1, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.5K
Antidiabetic plants improving insulin sensitivity
Mohamed Eddouks1, Amina Bidi, Bachir El Bouhali
1Faculty of Sciences and Techniques Errachidia, Moulay Ismail University, Errachidia, Morocco.
The Journal of Pharmacy and Pharmacology
|April 16, 2014
Summary
Medicinal plants show promise in managing insulin resistance, a key factor in diabetes mellitus. This review highlights 111 plants with potential hypoglycemic effects, offering natural avenues for diabetes management.
Area of Science:
- Pharmacology
- Phytomedicine
- Endocrinology
Background:
- Global rise in diabetes mellitus, driven by insulin deficiency and resistance.
- Insulin resistance increasingly diagnosed in diabetic and obese populations, particularly in industrialized nations.
- Conventional treatments for diabetes lack complete recovery; plants offer potential hypoglycemic agents.
Purpose of the Study:
- To review plants reported to improve insulin sensitivity in diabetes.
- Focus on medicinal plants as a source for antidiabetic drug discovery.
Main Methods:
- Systematic review of published literature.
- Analysis of in-vitro and in-vivo animal models of diabetes.
- Identification of plants with beneficial effects on insulin sensitivity.
Main Results:
- 111 medicinal plants identified with beneficial effects on insulin sensitivity.
- Evidence from various in-vitro and in-vivo studies supports these findings.
- Plants demonstrate diverse mechanisms in improving insulin sensitivity.
Conclusions:
- Medicinal plants play a significant role in managing insulin resistance associated with diabetes mellitus.
- These plants offer potential as alternative or complementary therapies.
- Further research into metabolic and cellular effects can optimize their use in diabetes care.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K